For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development | 36,053 | 22,010 | 22,547 | |
| General and administrative | 7,392 | 5,391 | 5,231 | |
| Total operating expenses | 43,445 | 27,401 | 27,778 | |
| Loss from operations | -43,445 | -27,401 | -27,778 | |
| Interest income | 3,102 | 2,254 | 1,828 | |
| Change in fair value of convertible notes payable | - | 0 | 6,184 | |
| Other expense | -9 | -28 | - | |
| Total other income (expense), net | 3,093 | 2,226 | -4,356 | |
| Net loss before income tax expense | -40,352 | - | - | |
| Income tax expense | 16 | - | - | |
| Net loss | -40,368 | -25,175 | -32,134 | |
| Currency translation adjustment | 2 | 18 | -24 | |
| Unrealized holding gain on investments | - | 35 | - | |
| Unrealized loss on investments | -473 | - | - | |
| Comprehensive loss | -40,839 | -25,122 | -32,158 | |
| Basic EPS | -0.57 | -0.48 | -0.86 | |
| Diluted EPS | -0.57 | -0.48 | -0.86 | |
| Basic Average Shares | 57,777,165 | 39,584,489 | 28,431,158 | |
| Diluted Average Shares | 57,777,165 | 39,584,489 | 28,431,158 | |
Jade Biosciences, Inc. (JBIO)
Jade Biosciences, Inc. (JBIO)